Live Breaking News & Updates on Isocabtagene Maraleuce

Stay updated with breaking news from Isocabtagene maraleuce. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Liso-cel Earns European Approval for Relapsed/Refractory LBCL After 1 Prior Therapy

The European Commission has approved lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
....

Anne Kerber , Cell Therapy Development At Bristol Myers Squibb , European Commission , Cell Therapy Development , Bristol Myers Squibb , Cart Cell Therapy , Global Oncology , Isocabtagene Maraleuce , Liso Cel , Diffuse Largeb Cell Lymphoma ,